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Voltage-dependent calcium channels (VDCCs) play an essential role in regulating cerebral
artery diameter and it is widely appreciated that the L-type VDCC, CaV1.2, encoded
by the CACNA1C gene, is a principal Ca2+ entry pathway in vascular myocytes.
However, electrophysiological studies using 10mM extracellular barium ([Ba2+]o) as a
charge carrier have shown that ∼20% of VDCC currents in cerebral artery myocytes
are insensitive to 1,4-dihydropyridine (1,4-DHP) L-type VDDC inhibitors such as
nifedipine. Here, we investigated the hypothesis that the concentration of extracellular
divalent cations can influence nifedipine inhibition of VDCC currents. Whole-cell VDCC
membrane currents were obtained from freshly isolated rat cerebral artery myocytes in
extracellular solutions containing Ba2+ and/or Ca2+. In the absence of [Ca2+]o, both
nifedipine-sensitive and -insensitive calcium currents were observed in 10mM [Ba2+]o.
However, VDCC currents were abolished by nifedipine when using a combination of
10mM [Ba2+]o and 100µM [Ca
2+]o. VDCC currents were also completely inhibited by
nifedipine in either 2mM [Ba2+]o or 2mM [Ca
2+]o. The biophysical characteristics of
all recorded VDCC currents were consistent with properties of a high-voltage activated
VDCC, such as CaV1.2. Further, VDCC currents recorded in 10mM [Ba
2+]o ± 100µM
[Ca2+]o or 2mM [Ba
2+]o exhibited similar sensitivity to the benzothiazepine L-type VDCC
blocker, diltiazem, with complete current inhibition at 100µM. These data suggest that
nifedipine inhibition is influenced by both Ca2+ binding to an external site(s) on these
channels and surface charge effects related to extracellular divalent cations. In sum,
this work demonstrates that the extracellular environment can profoundly impact VDCC
current measurements.
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INTRODUCTION
Members of the voltage-dependent calcium channel (VDCC) family are involved in a multitude
of physiological processes throughout the body. The classification of VDCC subtypes is based
on the amino acid sequence of the channels’ pore-forming alpha1-subunit, which principally
determines gating properties such as the voltage dependence of channel activation/inactivation
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and sensitivity to pharmacological agents (Catterall et al.,
2003; Alexander et al., 2015). It is widely appreciated that
the L-type VDCC, CaV1.2, encoded by the gene CACNA1C,
represents an important extracellular calcium ([Ca2+]o) entry
pathway involved in the regulation of bulk cytosolic Ca2+
and contraction of vascular smooth muscle, including cerebral
artery myocytes (Moosmang et al., 2003; Nystoriak et al., 2009).
For example, dynamic CaV1.2 gating in response to pressure-
dependent changes in smooth muscle membrane potential plays
a central role in modulating cerebral artery diameter and the
autoregulation of cerebral blood flow (Knot and Nelson, 1998;
Davis and Hill, 1999; Nystoriak et al., 2011). Further, 1,4-
dihydropyridines (1,4-DHPs), a class of compounds including
nifedipine and nimodipine, that are selective inhibitors of L-
type VDCCs have been used extensively in the treatment of
a wide range of cardiovascular disorders, including protection
against cerebral vasospasm following subarachnoid hemorrhage
(Wellman, 2006; Young et al., 2015).
Radioligand binding assays used to examine interactions
between 1,4-DHPs and CaV1.2 have shown the binding of
these two entities to be extremely dependent on the nature
and concentration of divalent cations present (Ebata et al.,
1990; Yamada et al., 1990; Hille, 2001; Nakajima et al., 2002).
Yamada et al., using porcine coronary artery preparations, found
that Ca2+ is required for high affinity binding of 1,4-DHPs to
CaV1.2, whereas Ba
2+ had the opposite effect, i.e., inhibition
of ligand/channel binding. Additional evidence indicates that it
is a Ca2+ binding site on the extracellular surface of CaV1.2
that promotes high affinity 1,4-DHP binding (Ebata et al., 1990).
However, because Ba2+ permeates several types of VDCCs more
effectively than Ca2+, Ba2+ has commonly been used as a charge
carrier during electrophysiological recordings to enhance the
amplitude of VDCC membrane currents in cells having low
channel number.
Using 10mM extracellular barium ([Ba2+]o) as a charge
carrier, several groups have shown that∼20% of VDCC currents
in cerebral artery myocytes are insensitive to high concentrations
(1µM) of nifedipine (Nikitina et al., 2007; Kuo et al., 2010;
Abd El-Rahman et al., 2013; Harraz and Welsh, 2013a). The
identity of these currents, often referred to as nifedipine-
insensitive calcium currents (NICCs), is controversial and several
VDCCs other than CaV1.2 have been implicated. The goal of
the present study was to examine the influence of [Ba2+]o
and [Ca2+]o on the efficacy of the 1,4-DHP, nifedipine, to
inhibit VDCC membrane currents in freshly isolated rat cerebral
artery myocytes. Our data indicate that the use of Ba2+ and/or
Ca2+ as charge carriers not only influences VDCC current
density, but also impacts the ability of nifedipine to inhibit these
currents.
MATERIALS AND METHODS
Animal Procedures
All procedures were conducted in accordance with the Guide for
the Care and Use of Laboratory Animals (eighth edition, 2011)
and followed protocols approved by the Institutional Animal
Care and Use Committee at the University of Vermont.
Male Sprague-Dawley rats (300–350 g) were euthanized
by decapitation under deep anesthesia with pentobarbital
(60mg/kg). Brains were removed from the skull and placed
in cold (∼3◦C) artificial cerebrospinal fluid (aCSF) of the
following composition: 125mM NaCl, 3mM KCl, 18mM
NaHCO3, 1.25mM NaH2PO4, 1mM MgCl2, 2mM CaCl2, and
5mM glucose, pH 7.30. Posterior cerebral arteries (PCAs) were
dissected from the brain and arachnoid membrane, then kept in
cold aCSF prior to cell isolation.
Isolation of Cerebral Artery Myocytes
Cerebral artery myocytes were enzymatically dissociated from
PCAs as previously described (Koide et al., 2007). Briefly, arteries
were first incubated in isolation solution containing 0.3mg/ml
papain and 0.7mg/ml dithioerythritol at 37◦C for 17 min. PCA
segments were then transferred to isolation solution containing
0.7mg/ml type F collagenase and 0.3mg/ml type H collagenase
and incubated at 37◦C for an additional 15 min. After the
second incubation period, arteries were washed three times with
cold isolation solution and triturated gently using a fire-polished
Pasteur pipette to disperse individual myocytes. Cells were kept
in isolation solution on ice and used for study within 6 h.
The isolation solution contained: 55mM NaCl, 80mM sodium
glutamate, 5.6mM KCl, 10mM HEPES, 2mM MgCl2, 100µM
CaCl2, and 10mM glucose (pH 7.30).
Measurement of VDCC Membrane
Currents
The conventional whole cell configuration of the patch clamp
technique was utilized to measure whole cell VDCC membrane
currents of cerebral artery myocytes using an Axopatch 200B
amplifier (Molecular Devices Corp., Sunnyvale, CA). The pipette
solution contained 130mM CsCl, 10mM EGTA, 10mMHEPES,
2mM ATP, 0.5mM GTP, 5mM phosphocreatine, and 10mM
glucose with pH adjusted to 7.20 with 1M CsOH. Patch pipettes
had resistances between 3 and 5 M when filled with pipette
solution. The extracellular solution contained 125mM NaCl,
10mM HEPES, 10mM glucose, 1mM MgCl2, 5mM KCl and
charge carrier (10mM Ba2+ or 10mM Ba2+ plus 100µM Ca2+
or 2mM Ba2+ or 2mM Ca2+) with pH adjusted to 7.40 with 1M
NaOH. Osmolarity of intracellular and extracellular solutions
were measured using a VAPRO vapor pressure osmometer
(Wescor Inc.) and were 295± 5 mOsm. Pipette offset, whole-cell
capacitance, and series resistance were compensated manually.
Cell capacitance of myocytes were 13.78 ± 0.31, 14.14 ±
0.29, 13.21 ± 0.27, and 13.68 ± 0.34 pF in 10mM [Ba2+]o,
10mM [Ba2+]o plus 100µM [Ca
2+]o, 2mM [Ba
2+]o, and 2mM
[Ca2+]o,respectively, and not significantly different between
groups. Series resistance measurements were 11.97 ± 1.31, 12.86
± 1.98, 10.19 ± 1.59, and 11.77 ± 0.94 M in 10mM [Ba2+]o,
10mM [Ba2+]o plus 100µM [Ca
2+]o, 2mM [Ba
2+]o, and 2mM
[Ca2+]o, respectively, and were also not significantly different
between groups.
Myocytes were voltage clamped at a holding potential of
−80mV for ∼5 min prior to the start of an experimental series.
During this initial period, single depolarizing steps to +10mV
were applied to cells to ensure current amplitudes were stable
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before starting experimental protocols. Voltage protocols were
driven and data were acquired using pCLAMP 9.2 software
(Molecular Devices Corp., Sunnyvale, CA). Current traces were
filtered at 1 kHz with a low-pass filter, subjected to P/4 leak
subtraction and digitized at 5 kHz. Current-voltage relationships
were obtained in response to a series of successive 10mV
depolarizing voltage steps (800ms in duration) from the holding
potential of −80mV to +50mV at 5 s intervals. Steady-state
activation curves were also obtained using this protocol by
measuring currents at the end of the 800ms voltage step and
dividing these measurements by peak currents obtained for each
cell to obtain I/Imax. These values were then plotted against
test voltage to calculate the half-activation voltage (V0.5 act).
In some cells, a voltage ramp protocol was used that applied
a continuous depolarization from −80 to +50mV over the
course of 300ms. Concentration-response relationships for the
inhibition of VDCC currents by nifedipine and diltiazem were
obtained in separate cells where currents were evoked by a
single 200ms duration voltage step from a holding potential of
−80 to +10mV. Solution changes were made via perfusion of
the recording chamber (chamber volume: ∼500µl) for 10 min
at a flow rate of ∼1.9ml/min. Steady-state inactivation curves
were obtained using a double-step voltage protocol that applied
a 5 s conditioning pulse step from −80 to +40mV (10mV
increments) followed by a return to −80mV for 15ms and then
150ms test voltage step to 10mV. All current recordings were
done at room temperature (20–22◦C).
Drugs and Reagents
All chemicals and reagents including nifedipine and diltiazem
were purchased from Sigma-Aldrich (St. Louis, MO) with the
exception of papain, which was purchased from Worthington
Biochemical Corp. (Lakewood, NJ).
Data Analysis and Statistics
Data were analyzed using Clampfit 9.2 software (Molecular
Devices Corp., Sunnyvale, CA) as current density by dividing
current amplitude by cell capacitance and are expressed as
mean ± standard error of the mean (SEM). The number
of cells in each dataset is denoted as “n” followed by the
number of rats from which cells were obtained. The paired t-
test was used for paired-sample analysis. For multiple group
comparisons, data were initially evaluated by one-way ANOVA,
with a p < 0.05 considered statistically significant followed
by paired comparisons between two groups using Tukey’s
multiple comparisons post-test. The voltages for half-maximal
activation (V0.5act) and half-maximal inactivation (V0.5inact)
were obtained from Boltzman fit of steady-state activation
and inactivation curves. Concentration-inhibition curves for
nifedipine or diltiazem were calculated after normalization to
currents in the absence of drug and fitted to the following
equation: y = Imax/{1 + ([drug]/Ki)nH}+r, where Imax, [drug],
Ki, nH, and r represent the maximum currents density,
concentration of drug, binding affinity of drug, Hill coefficient,
and drug resistant currents, respectively (Ebata et al., 1990). The
IC50 of a drug was determined from concentration-inhibition
curves.
RESULTS
Nifedipine Inhibition of VDCC Currents
Using 10mM [Ba2+]o as a Charge Carrier
Using 10mM [Ba2+]o as a charge carrier, VDCC currents
were elicited in rat cerebral artery myocytes by a series of
10mV depolarizing steps from a holding potential −80mV. In
nominally Ca2+ free 10mM Ba2+ bath solution, a maximum
VDCC current density of −7.30 ± 0.35 pA/pF (n = 8 cells
from four animals) was observed at +10mV (Figures 1A,C).
In the presence of nifedipine (1µM), VDCC currents were
reduced, but not abolished (Figures 1B,C). At +10mV, the
nifedipine-insensitive current density (−1.62 ± 0.48 pA/pF)
was ∼22% of total VDCC current density measured in these
cells. To examine the impact of [Ca2+]o on VDCC currents
when 10mM [Ba2+]o is used as the primary charge carrier,
the above voltage-step protocol was repeated using myocytes
bathed in a combination of 10mM [Ba2+]o and 100µM [Ca
2+]o
(Figures 1D–F). The VDCC current density recorded at+10mV
(−7.28 ± 0.54 pA/pF; n = 11 cells, seven animals) was
not significantly different compared to VDCC current density
measured in 10mM [Ba2+]o, alone (Figure 1C). However, the
addition of 100µM [Ca2+]o dramatically influenced the efficacy
of nifedipine to inhibit VDCC currents. As illustrated in
Figure 1F, inward VDCC currents obtained in the combination
of 10mM [Ba2+]o and 100µM [Ca
2+]o were completely
abolished by 1µM nifedipine. To further investigate the impact
of [Ca2+]o on VDCC currents, single depolarizing voltage
steps from a holding potential of −80 to +10mV were
used to elicit VDCC currents in the presence of increasing
concentrations of nifedipine (10−10–10−6 M) followed by
drug washout (Figures 2A–E and Table 2). In 10mM [Ba2+]o,
nifedipine caused a concentration-dependent decrease in VDCC
currents with an IC50 of 6.02 ± 0.36 nM (n = 5 cells from
five animals) with ∼20% of the current insensitive to 1µM
nifedipine. Addition of 100µM [Ca2+]o to the 10mM [Ba
2+]o
bath solution again facilitated the complete inhibition of VDCC
currents by 1µM nifedipine, but did not change VDCC
sensitivity to nifedipine (IC50 value 5.12 ± 0.41 nM; n = 4
cell from three animals). Upon washout of 1µM nifedipine,
current density was not significantly different when compared
to current density obtained prior to the start of the nifedipine
concentration-response curve (Table 2). Current-voltage (I-V)
plots shown in Figures 1C,F are consistent with the activation
of high-voltage activated VDCCs, i.e., maximum current density
was observed at ∼+10mV. To obtain higher resolution with
respect to the voltage-dependent activation of VDCC currents,
voltage ramp protocols were used that applied a continuous
depolarization from a holding potential of −80 to +50mV
over the course of 300ms (Figures 2D–F). This approach also
enabled the study of the same cell using 10mM [Ba2+]o as
the charge carrier in the presence and absence of 100µM
[Ca2+]o (Figures 2D–F). No difference was detected in the
membrane potential that evoked maximum VDCC currents in
10mM [Ba2+]o in the absence or presence of 100µM [Ca
2+]o
(9.99 ± 0.08 vs. 10.01 ± 0.08mV; n = 5 cells from three
animals; p > 0.05). Maximum VDCC current density in cells
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FIGURE 1 | Nifedipine inhibition of VDCC currents obtained in 10mM [Ba2+]o ± 100µM [Ca
2+]o. VDCC currents were elicited in rat cerebral artery myocytes
in response to successive 10mV depolarizing voltage steps from a holding potential of −80mV. (A,B) VDCC currents obtained using 10mM [Ba2+]o as the charge
carrier in nominally Ca2+-free extracellular solution in the absence (A) and presence (B) of nifedipine (1µM). (C) Summary data demonstrating that ∼20 % of VDCC
currents using 10mM [Ba2+]o were not inhibited by 1µM nifedipine. (D,E) VDCC currents obtained using 10mM [Ba
2+]o plus 100µM [Ca
2+]o in the absence (D)
and presence (E) of nifedipine (1µM). (F) Summary data demonstrating that VDCC currents were completely inhibited by 1µM nifedipine in 10mM [Ba2+]o plus
100µM [Ca2+]o.
bathed in 10mM [Ba2+]o was also not significantly different
in the absence or presence of 100µM [Ca2+]o (Figures 2G–I).
Voltages for half-maximal inactivation (V0.5inact) were ∼−13.9,
−32.5, and −19.9mV in 10mM [Ba2+]o, 10mM [Ba
2+]o +
nifedipine (1µM) and 10mM [Ba2+]o + 100µM [Ca
2+]o,
respectively (Figures 3A–D and Table 1) Voltages for half-
maximal activation (V0.5act) were similar in 10mM [Ba
2+]o
± 100µM [Ca2+]o, but were shifted modestly (∼+8mV) in
10mM [Ba2+]o plus 1µM nifedipine (Figure 3E and Table 1).
In addition to 1,4-DHPs (e.g., nifedipine), L-type VDCCs
are inhibited by benzothiazepines such as diltiazem. Figure 4
illustrates the concentration dependent inhibition by diltiazem
of VDCC currents in 10mM [Ba2+]o ± 100µM [Ca
2+]o.
In contrast to the actions of nifedipine, diltiazem (100µM)
caused complete inhibition of 10mM [Ba2+]o VDCC currents
irrespective of the presence or absence of 100µM [Ca2+]o.
Upon washout of 100µM diltiazam, current density was not
significantly different when compared to a current density
obtained prior to the start of the diltiazem concentration-
response curve (Table 2).
Nifedipine Inhibition of VDCC Currents
Using 2mM [Ba2+]o or 2mM [Ca
2+]o as a
Charge Carrier
Surface charges, influenced by the concentration of extracellular
divalent cations can impact VDCC properties, including
drug/ligand binding (Kass and Krafte, 1987). To examine the
impact of divalent cation concentration on nifedipine inhibition,
VDCC currents were recorded in cerebral artery myocytes in
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FIGURE 2 | Properties of VDCC currents obtained using 10mM [Ba2+]o ± 100µM [Ca
2+]o. (A–C) VDCC currents elicited by depolarizing voltage steps to
+10mV from a holding potential of −80mV. (A) Effect of increasing concentrations of nifedipine in 10mM [Ba2+]o. (C) Effect of increasing concentrations of nifedipine
in 10mM [Ba2+]o plus 100µM [Ca
2+]o. Traces in red represent currents obtained in cells prior to the addition of nifedipine. Traces in blue represent current traces
obtained in cells following washout of 1µM nifedipine. (C) Concentration-inhibition curves of nifedipine on VDCC currents obtained in bath solution containing 10mM
[Ba2+]o ± 100µM [Ca
2+]o. (D–F) VDCC currents evoked using a voltage ramp protocol that applied a continuous membrane potential depolarization from −80 to
+50mV over the course of 300ms. (D) VDCC currents from a cerebral artery myocyte in bath solution containing 10mM [Ba2+]o. (E) VDCC currents from the same
cell depicted in (D) in bath solution containing 10mM [Ba2+]o plus 100µM [Ca
2+]o. (F) Summary data demonstrating that the membrane potential evoking maximum
VDCC current density was not different in bath solution containing 10mM [Ba2+]o ± 100µM [Ca
2+]o (paired t-test, p > 0.05). (G–I) VDCC currents evoked by
voltage steps to +10mV in cells in bath solution containing 10mM [Ba2+]o ± 100µM [Ca
2+]o. Maximum current density at +10mV was not different between
groups (paired t-test, p > 0.05).
Ca2+-free extracellular solution containing 2mM [Ba2+]o as a
charge carrier (Figures 5A–C). As expected, maximum current
density in 2mM [Ba2+]o (−3.77 ± 0.37 pA/pF at +10mV;
n = 13 cells from eight animals) was decreased compared to
VDCC current density obtained in 10mM [Ba2+]o. However, in
contrast to currents obtained in 10mM [Ba2+]o, VDCC currents
were completely inhibited by 1µM nifedipine in 2mM [Ba2+]o.
Similarly, VDCC currents were abolished by 1µM nifedipine
when 2mM [Ca2+]o was used in place of 2mM [Ba
2+]o as a
charge carrier (Figures 5D–F). Nifedipine IC50 values in 2mM
[Ba2+]o were 1.85 ± 0.29 nM, n = 5 cells from two animals) and
were 3.35± 0.34 nM, (n= 4 cells from four animals, Figure 6) in
2mM [Ca2+]o. Diltiazem IC50 value of VDCC currents recorded
in 2mM [Ba2+]o was 1.88± 0.25µM, n= 4 from three animals.
Upon washout of nifedipine and diltiazem, current density was
not significantly different when compared to a current density
obtained prior to drug application (Figure 6 and Table 2). Values
obtained for V0.5act and V0.5inact were similar between cells
bathed in solution containing 2mM [Ba2+]o and 2mM [Ca
2+]o
(Table 1).
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FIGURE 3 | Voltage-dependent inactivation and activation characteristics of VDCC currents recorded in 10mM [Ba2+]o ± 100µM [Ca
2+]o.
(A–C) Current recordings obtained from cells using a double-step voltage protocol that applied a 5 s conditioning pulse step to examine steady-state VDCC
inactivation. Recordings obtained in extracellular solution containing 10mM [Ba2+]o (A), 10mM [Ba
2+]o with 1µM nifedipine (B), and 10mM [Ba
2+]o plus 100µM
[Ca2+]o (C). (D) Steady-state inactivation curves obtained using the voltage protocol illustrated in (A–C). (E) VDCC activation curves derived from currents elicited by
successive 10mV depolarizing voltage steps from a holding potential of −80mV.
TABLE 1 | VDCC current properties.
Extracellular divalent cation Voltage of half activation (mv) Voltage of half inactivation (mv) IC50 for nifedipine (nm) IC50 for diltiazem (µm)
10mM [Ba2+]o −7.06 ± 0.85
b, (n = 16) −13.52 ± 0.85a,b, (n = 13) 6.02 ± 0.36, (n = 5) 1.00 ± 0.29, (n = 6)
10mM [Ba2+]o with 1µM nifedipine 1.51 ± 0.96, (n = 8) −32.46 ± 1.05, (n = 4)
10mM [Ba2+]o plus 100µM [Ca
2+]o −6.99 ± 0.55, (n = 11) −19.69 ± 0.63, (n = 4) 5.12 ± 0.41, (n = 4) 1.92 ± 0.57, (n = 4)
2mM [Ba2+]o −11.44 ± 0.61, (n=13) −21.98 ± 0.71, (n = 8) 1.85 ± 0.29
c, (n = 5)
2mM [Ca2+]o −9.17 ± 0.70, (n=10) −25.00 ± 0.82, (n = 7) 3.35 ± 0.34, (n = 4)
ap < 0.05 vs. 10mM [Ba2+ ]o plus 100µM [Ca
2+ ]o.
bp < 0.05 vs. 10mM [Ba2+ ]o with 1µM nifedipine.
cp < 0.05 vs. 2mM [Ca2+ ]o.
DISCUSSION
This study demonstrates that the composition of extracellular
divalent cations can profoundly alter the inhibition of whole-
cell VDCC currents by 1,4-DHPs such as nifedipine. Our data
indicate that nifedipine inhibition of VDCC currents in rat
cerebral artery myocytes can be influenced by two factors: (1)
the presence or absence of 100µM [Ca2+]o when using 10mM
[Ba2+]o as a charge carrier— an effect likely mediated by the
interaction of Ca2+ with an extracellular VDCC binding site and
(2) the concentration of the extracellular divalent cation used as
a charge carrier— an effect likely mediated by a change in surface
charge. Further, these findings support the functional presence
of a single population of high-voltage activated VDCCs in rat
cerebral artery myocytes and demonstrate that the inhibition of
these channels by nifedipine can be influence by the extracellular
environment.
As depicted in Figure 1, nifedipine-resistant VDCC currents
are absent when 100µM Ca2+ is included in the extracellular
solution during conventional whole-cell current recordings. This
finding is consistent with a body of previous work indicating
that the extracellular VDCC binding site for Ca2+ is coupled
Frontiers in Physiology | www.frontiersin.org 6 April 2017 | Volume 8 | Article 210
Wang et al. Nifedipine Inhibition of VDCC Currents
FIGURE 4 | Diltiazem abolishes VDCC currents in 10mM [Ba2+]o ± 100µM [Ca
2+]o. VDCC currents elicited by depolarizing voltage steps to +10mV from a
holding potential of −80mV in bath solutions containing 10mM [Ba2+]o (A) or 10mM [Ba
2+]o plus 100µM [Ca
2+]o (B). Traces in red represent currents obtained in
cells prior to the addition of diltiazem. Traces in blue represent current traces obtained in cells following washout of 100µM diltiazem. (C) Concentration-inhibition
curves of diltiazem on VDCC currents obtained in extracellular solution containing 10mM [Ba2+]o ± 100µM [Ca
2+]o.
TABLE 2 | VDCC current density ± nifedipine or diltiazem.
VDCC current density (pA/pF) VDCC current density (pA/pF)
Before drug Nifedipine After drug Before drug Diltiazem After drug
application 10−6 M washout application 10−4 M washout
10mM [Ba2+]o −7.35 ± 0.57
# −1.42 ± 0.58 −7.01 ± 0.65 −7.13 ± 0.59# −0.09 ± 0.18 −6.93 ± 0.58
10mM [Ba2+]o plus 100µM [Ca
2+]o −7.29 ± 0.66
# −0.13 ± 0.70 −6.95 ± 0.67 −6.94 ± 0.52# −0.16 ± 0.15 −6.90 ± 0.44
2mM [Ba2+]o −3.52 ± 0.33
# −0.17 ± 0.15 −3.36 ± 0.30 −3.37 ± 0.38# −0.07 ± 0.09 −3.43 ± 0.41
2mM [Ca2+]o −2.29 ± 0.45
# −0.22 ± 0.12 −2.16 ± 0.39 – – –
#not significantly different compared to after drug washout (p > 0.05).
to a 1,4-DHP binding site on the channel and that [Ca2+]o
is required for high affinity 1,4-DHP binding (Ebata et al.,
1990; Knaus et al., 1992; Nakajima et al., 2002). Further, a K0.5
of 300 nM for [Ca2+]o to stabilize the high affinity binding
domain for 1,4-DHPs was reported in L-type VDCC purified
from rabbit skeletal muscle (Staudinger et al., 1991). In our
study, the addition of 100µM [Ca2+]o enabled the complete
inhibition of VDCC currents by 1µM nifedipine, but did not
change VDCC sensitivity to nifedipine, with IC50 values similar
± [Ca2+]o (Figure 2). This observation is consistent with the
work of Yamada et al. that reported a reduction in the maximum
number of high affinity 1,4-DHP binding sites either in the
presence of [Ba2+]o or the absence of [Ca
2+]o in porcine
coronary artery preparations (Yamada et al., 1990). In addition to
1,4-DHPs, L-type VDCCs are selectively inhibited by two other
classes of compounds, benzothiazepines, and phenylalkylamines,
with each class of inhibitors having distinct binding sites
to the VDCC alpha1 subunit (Hille, 2001). We found the
efficacy of the benzothiazepine, diltiazem, to be independent
of [Ca2+]o. In effect, diltiazem (100µM) completely abolished
10mM [Ba2+]o VDCC currents irrespective of the presence or
absence of [Ca2+]o (Figure 4), consistent with the existence of
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FIGURE 5 | Nifedipine inhibition of VDCC currents obtained in 2mM [Ba2+]o or 2mM [Ca
2+]o. VDCC currents were elicited in rat cerebral artery myocytes in
response to successive 10mV depolarizing voltage steps from a holding potential of −80mV. (A,B) VDCC currents obtained using 2mM [Ba2+]o as the charge carrier
in nominally Ca2+-free extracellular solution in the absence (A) and presence (B) of nifedipine (1µM). (C) Summary data demonstrating that VDCCs currents were
completely inhibited by 1µM nifedipine in bath solution containing 2mM [Ba2+]o. (D,E) VDCC currents obtained using 2mM [Ca
2+]o in the absence (D) and presence
(E) of nifedipine (1µM). (F) Summary data demonstrating that VDCC currents were completely inhibited by 1µM nifedipine in bath solution containing 2mM [Ca2+]o.
independent binding sites for 1,4-DHPs and benzothiazepines.
This observation supports the work of other groups that have
shown that L-type VDCC mutations that prevent 1,4-DHP
binding do not alter channel inhibition by diltiazem (Yamaguchi
et al., 2000; Walsh et al., 2007).
Our data indicate that surface charge, influenced by the
concentration of extracellular divalent cations, can also affect
inhibition of L-type VDCCs by nifedipine. As shown in
Figures 5, 6, decreasing the extracellular concentration of Ba2+
from 10 to 2mM dramatically increased VDCC inhibition
by nifedipine. In this case, the change in nifedipine efficacy
was independent of [Ca2+]o, as the experimental series was
done in nominally Ca2+-free extracellular solution. These
findings are remarkably similar to those reported by Kass and
Krafte examining nisoldipine block of L-type VDCC in cardiac
myocytes (Kass and Krafte, 1987). These investigators provided
evidence that a depolarizing shift in surface charge and the
resulting impact on channel gating was largely responsible for
the apparent antagonism between divalent cations and 1,4-
DHPs. In our present study, V0.5act was shifted positively
from −22.0 to −13.5mV when 2mM [Ba2+]o was replaced
with 10mM [Ba2+]o, indicative of a depolarizing shift in
surface charge. However, additional mechanisms independent
of the effects of surface charge on VDCC gating such
as direct interaction of divalent cations with the 1,4-DHP
binding site may also contribute to nifedipine-resistant currents
observed in the presence of higher concentrations of divalent
cations.
Our data are consistent with the presence of high-
voltage activated L-type VDCCs in cerebral artery myocytes
(Figures 1, 2, 5). Under physiological conditions, i.e., 2mM
[Ca2+]o, 1,4-DHPs would be predicted to inhibit these channels,
as has been shown in a number of functional studies (Knot and
Nelson, 1998; Gokina and Osol, 2002; Wellman et al., 2002;
Ishiguro et al., 2005; Syyong et al., 2009). Interestingly, other
studies using a combination of ex vivo diameter measurements,
molecular biology, western blotting, and electrophysiology
indicate the co-existence of nifedipine-insensitive low-voltage
activated T-type VDCCs (CaV3.x family members) along with
L-type VDCCs in cerebral artery myocytes (Kuo et al., 2010; Abd
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FIGURE 6 | Concentration-dependent inhibition of VDCC currents by nifedipine in 2mM [Ba2+]o or 2mM [Ca
2+]o. VDCC currents elicited by depolarizing
voltage steps to +10mV from a holding potential of −80mV. (A) Effect of increasing concentrations of nifedipine in bath solution containing 2mM [Ba2+]o. (B) Effect
of increasing concentrations of nifedipine in bath solution containing 2mM [Ca2+]o. Traces in red represent currents obtained in cells prior to the addition of nifedipine.
Traces in blue represent current traces obtained in cells following washout of 1µM nifedipine. (C) Concentration-inhibition curves of nifedipine on VDCC currents
obtained in bath solution containing either 2mM [Ba2+]o or 2mM [Ca
2+]o.
El-Rahman et al., 2013; Harraz and Welsh, 2013b; Harraz et al.,
2015). In the current study, the current- voltage relationships
that were obtained are consistent with those of high-voltage
activated VDCCs, rather than with properties characteristic
of those reported for T-type VDCCs (Lambert et al., 2014).
Further, the modest depolarizing shift in the current-voltage
relationship of nifedipine-resistant currents obtained in 10mM
Ba2+ is also not consistent with the presence of T-type channels.
Presently, the reason why T-type VDCC currents were detected
in the above-mentioned studies, but not in our study is
unclear.
In conclusion, this study demonstrates that the composition of
extracellular divalent cations can profoundly impact the binding
of 1,4-DHPs to L-type VDCCs. These findings suggest that
measurements of VDCC currents should be preferentially carried
out in physiological concentrations of divalent cations.
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